Dario Bottigliero

Dr. Dario Bottigliero

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IMIlenia Monaco
Ilenia Monaco
MSMounia Sedrati
Mounia Sedrati
ICInsaf Chouarfia
Insaf Chouarfia
FBFatima S. Bouhaik
Fatima S. Bouhaik
VTValeria Trivelloni
Valeria Trivelloni
DBDario Bottigliero
Dario Bottigliero
Background Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable cause of heart failure has increased. There are striking sex differences in diagnosis, clinical course, and outcome. Notably, women have a worse prognosis than men with similar amounts of cardiac involvement. Methods This review provides an overview of the current state of knowledge on the epidemiology, clinical features, diagnosis and treatment of amyloid heart disease. The differences observed between men and women are discussed and recent advances in the field are highlighted. Results Compared with men, women are generally older at diagnosis, appear to have less severe cardiac disease at time of impairment and are given a late diagnosis. The less apparent disease in women may be responsible for the delay in diagnosis. Women may be under-diagnosed using neutral sex diagnostic criteria. Conclusions Addressing diagnostic disparities may require the use of sex-specific diagnostic thresholds, as well as a more expansive use of multimodality imaging. Future studies trials should aim to enroll greater numbers of female participants to inform optimal therapeutic approaches and to define the sex-specific disease phenotype for this increasingly treatable disease.

13 May 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YBYassine Bencharef
Yassine Bencharef
IMIlenia Monaco
Ilenia Monaco
FSFouad M. Sekkal
Fouad M. Sekkal
MSMounia Sedrati
Mounia Sedrati
ICInsaf Chouarfia
Insaf Chouarfia
DBDario Bottigliero
Dario Bottigliero
Background: Transthyretin amyloidosis (ATTR) is a rare, often underdiagnosed and undertreated, autosomal dominantly inherited, progressive disease that affects multiple systems of the body. It results from the extracellular accumulation of misfolded transthyretin (TTR) protein as insoluble amyloid fibrils, predominantly causing cardiomyopathy, polyneuropathy or mixed phenotypes. It can occur in a hereditary form (ATTRv) and in a wild-type form (ATTRwt), with over 150 different pathogenic mutations having been identified worldwide. The clinical presentation is highly variable, leading to a diagnostic delay of 2–5 years. Transthyretin (TTR) amyloidosis is an inherited disease for which recent advances in pathogenesis, diagnosis and treatment have revolutionized its management. Objectives: The aims of this review are to provide an update on the epidemiology and genotype-phenotype correlation, on current diagnostic techniques and on emerging and individualized treatments for this rare hereditary disease. Particular attention will be given to the early diagnosis Methods: A systematic literature search was conducted across major databases to identify studies addressing clinical characteristics, diagnostic modalities, and treatment outcomes in hereditary and wild-type ATTR amyloidosis. Registry data from THAOS and other multinational cohorts were analyzed to evaluate phenotypic variability across genotypes and geographic regions. Results: Clinical presentation of TTR related amyloidosis (h-Amyloid) can range from early onset to late onset with late onset having worse neurological and cardiac involvement at time of diagnosis. The Val30Met mutation is the most common TTR mutation worldwide, however patients with non-V30M mutations can have very different presentations of h-amyloidosis. Identifying “red flag” symptoms in a patient with suspicious clinical presentation can initiate correct diagnostic pathway. Non-invasive imaging, especially bone scintigraphy, has greatly facilitated the diagnosis of patients with Transthyretin related cardiac amyloidosis (ATTR-CM). First generation h-amyloid treatments or TTR stabilizers such as tafamidis have been shown to significantly improve survival in patients with h-amyloidosis. The second generation treatments such as RNA silencers (patisiran, vutrisiran, inotersen, eplontersen) have been shown to halt the disease progression. Present data from small to moderate-sized patient cohorts demonstrate that TTR-targeting therapy is associated with reduction of cardiovascular events and improvement in survival compared with current standard of care. Early recognition of key clinical features and application of a diverse diagnostic strategy, in conjunction with timely initiation of disease-modifying therapy, are critical to optimal management of patients with hereditary transthyretin (ATTR) amyloidosis. Conclusions: The therapeutic options have evolved and improved in recent years, and with current diagnostic tools, the opportunity to alter the natural history of a disease that was once invariably fatal is better than ever. Because the disease is systemic, a thorough, multidisciplinary approach to patient management is ideal.